236 related articles for article (PubMed ID: 35969896)
1. Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach.
Aliyu M; Zohora FT; Anka AU; Ali K; Maleknia S; Saffarioun M; Azizi G
Int Immunopharmacol; 2022 Oct; 111():109130. PubMed ID: 35969896
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-6: A Masterplayer in the Cytokine Network.
Uciechowski P; Dempke WCM
Oncology; 2020; 98(3):131-137. PubMed ID: 31958792
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway.
Chetoui N; Boisvert M; Gendron S; Aoudjit F
Immunology; 2010 Jul; 130(3):418-26. PubMed ID: 20465565
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells.
Russell MA; Cooper AC; Dhayal S; Morgan NG
Islets; 2013; 5(2):95-105. PubMed ID: 23510983
[TBL] [Abstract][Full Text] [Related]
5. Underpinning IL-6 biology and emphasizing selective JAK blockade as the potential alternate therapeutic intervention for rheumatoid arthritis.
Srivastava S; Rasool M
Life Sci; 2022 Jun; 298():120516. PubMed ID: 35367240
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis.
Benveniste EN; Liu Y; McFarland BC; Qin H
J Interferon Cytokine Res; 2014 Aug; 34(8):577-88. PubMed ID: 25084174
[TBL] [Abstract][Full Text] [Related]
7. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
[TBL] [Abstract][Full Text] [Related]
9. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
Welsch K; Holstein J; Laurence A; Ghoreschi K
Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
[TBL] [Abstract][Full Text] [Related]
10. The tyrosine phosphatase SHP2 increases robustness and information transfer within IL-6-induced JAK/STAT signalling.
Fiebelkow J; Guendel A; Guendel B; Mehwald N; Jetka T; Komorowski M; Waldherr S; Schaper F; Dittrich A
Cell Commun Signal; 2021 Sep; 19(1):94. PubMed ID: 34530865
[TBL] [Abstract][Full Text] [Related]
11. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
Tanaka T; Narazaki M; Ogata A; Kishimoto T
Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
[TBL] [Abstract][Full Text] [Related]
12. Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS; Lee JY; Yang JW; Lee KH; Effenberger M; Szpirt W; Kronbichler A; Shin JI
Theranostics; 2021; 11(1):316-329. PubMed ID: 33391477
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.
Olson KC; Kulling Larkin PM; Signorelli R; Hamele CE; Olson TL; Conaway MR; Feith DJ; Loughran TP
Cytokine; 2018 Nov; 111():551-562. PubMed ID: 30455079
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.
Liu Y; Holdbrooks AT; De Sarno P; Rowse AL; Yanagisawa LL; McFarland BC; Harrington LE; Raman C; Sabbaj S; Benveniste EN; Qin H
J Immunol; 2014 Jan; 192(1):59-72. PubMed ID: 24323580
[TBL] [Abstract][Full Text] [Related]
15. Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.
Waldmann TA; Chen J
Annu Rev Immunol; 2017 Apr; 35():533-550. PubMed ID: 28182501
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
Ohsugi Y
Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6: designing specific therapeutics for a complex cytokine.
Garbers C; Heink S; Korn T; Rose-John S
Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
[TBL] [Abstract][Full Text] [Related]
19. The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels.
Isomäki P; Junttila I; Vidqvist KL; Korpela M; Silvennoinen O
Rheumatology (Oxford); 2015 Jun; 54(6):1103-13. PubMed ID: 25406356
[TBL] [Abstract][Full Text] [Related]
20. Withasteroid B from D. metel L. regulates immune responses by modulating the JAK/STAT pathway and the IL-17
Su Y; Wang Q; Yang B; Wu L; Cheng G; Kuang H
Clin Exp Immunol; 2017 Oct; 190(1):40-53. PubMed ID: 28617942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
